Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna (MRNA) remains at the forefront of mRNA technology innovation, developing transformative therapies for infectious diseases, oncology, and rare conditions. This dedicated news hub provides investors and healthcare professionals with essential updates directly from the company and verified sources.
Access official press releases covering clinical trial results, regulatory milestones, and strategic partnerships, alongside analysis of quarterly earnings and pipeline developments. Our curated collection ensures you stay informed about Moderna's progress in advancing mRNA-based medicines without promotional bias.
Key updates include developments in respiratory vaccines, cancer immunotherapy candidates, and rare disease treatments. Bookmark this page for real-time access to Moderna's verified announcements and objective reporting on one of biotechnology's most innovative platforms.
Moderna (Nasdaq: MRNA) has initiated the Phase 1/2 study of its mRNA-1010 vaccine, targeting seasonal influenza. The study involves approximately 180 healthy adults aged 18 and older in the U.S. The quadrivalent vaccine aims to protect against significant influenza lineages as recommended by WHO. This is Moderna's first seasonal influenza vaccine candidate entering clinical trials, marking a significant step in its mRNA vaccine strategy. The company envisions developing combination vaccines for multiple respiratory viruses, aiming to enhance public health response.
Moderna (Nasdaq: MRNA) has commenced the manufacturing of its COVID-19 vaccine at Recipharm’s Monts site in France, following the European Medicines Agency's approval on June 11, 2021. This collaboration aims to bolster vaccine production capacity in Europe, essential for ongoing vaccination efforts. Moderna's recent investments are set to double drug substance manufacturing across Europe and enhance safety stock of raw materials. The COVID-19 Vaccine Moderna has received marketing authorization in 49 countries and is integral to Moderna's strategic growth in mRNA therapeutics.
Moderna (Nasdaq: MRNA) has received authorization from the government of India for its COVID-19 vaccine for emergency use in adults aged 18 and older. This marks a significant milestone in the global fight against the pandemic. The vaccine is already authorized in over 50 countries and has received Emergency Use Listing from the WHO. Moderna, recognized for its rapid development capabilities, continues to expand its mRNA platform with ongoing development programs across various therapeutic areas.
Moderna (Nasdaq: MRNA) announced new findings from in vitro studies showing that its COVID-19 Vaccine effectively produces neutralizing titers against various SARS-CoV-2 variants. Vaccination elicited neutralization against all tested variants, including Beta, Delta, and others. Although some variants showed reduced antibody response, overall effectiveness remains promising. Moderna is actively studying new variants and developing a multivalent booster candidate. The mRNA platform continues to support vaccine development initiatives to combat evolving strains of the virus.
Moderna (NASDAQ: MRNA) announces that Kate Cronin will join as Chief Brand Officer on July 12, 2021. She will be part of the Executive Committee, reporting to CEO Stéphane Bancel. Cronin, previously Global CEO at Ogilvy Health, brings extensive experience in brand strategy and marketing in the biopharmaceutical sector. She aims to enhance Moderna's brand and communicate its potential in mRNA therapeutics. Moderna continues to evolve, with a diverse pipeline and a strong commitment to advancing mRNA science in vaccines and therapeutics.
Moderna, Inc. (Nasdaq: MRNA) announced the European Commission's purchase of an additional 150 million doses of its COVID-19 vaccine, raising total commitments to 460 million doses. Deliveries of the updated vaccine are set to begin in 2022, pending regulatory approval. Initial Phase 2 study data revealed that a 50 µg booster dose significantly increased neutralizing antibodies against SARS-CoV-2 variants. Moderna continues to meet its EU delivery commitments for 2021, supported by its mRNA platform and expanded manufacturing capabilities.
Moderna (Nasdaq: MRNA) has significantly expanded its workforce in Massachusetts, increasing from approximately 830 to 1,500 employees between March 2020 and March 2021. The company has created over 650 new jobs at its Norwood manufacturing facility. Moderna received a tax incentive from the Massachusetts Life Sciences Center for its commitment to employ 155 new full-time staff until 2025. A recent expansion in Norwood will boost Moderna's COVID-19 vaccine production capacity by 50%, aiming for up to 3 billion doses by 2022.
Moderna (Nasdaq: MRNA) has announced a U.S. government purchase of an additional 200 million doses of its COVID-19 vaccine, bringing the total confirmed commitment to 500 million doses. Deliveries include 110 million doses in Q4 2021 and 90 million in Q1 2022. As of June 14, 2021, Moderna has supplied 217 million doses. CEO Stéphane Bancel emphasized the collaboration's importance for vaccination efforts, including potential boosters. The company has received various authorizations globally for its vaccine and continues research funded by the U.S. government.
Moderna (Nasdaq: MRNA) has partnered with Magenta Investments to distribute the Moderna COVID-19 Vaccine and updated variant booster candidates in the UAE for 2021 and 2022. This agreement aims to enhance vaccine access in the region as part of a global effort against the COVID-19 pandemic. The Moderna vaccine utilizes an mRNA platform and has received various emergency authorizations across numerous countries. Moderna's commitment to innovation in vaccine technology continues to drive its position in the biopharmaceutical industry.
Rafael Holdings, Inc. (NYSE: RFL) announced the appointment of three new members to its Board of Directors: Ameet Mallik, CEO; Shannon Thyme Klinger, Chief Legal Officer of Moderna; and Mark McCamish, CEO of IconOVir Bio. Chairman Howard Jonas expressed optimism, stating the new board members bring significant expertise to advance the company's oncology pipeline. Ameet Mallik highlighted the importance of their industry experience in maximizing the potential of their therapeutics.